Molecular-targeted anticancer therapy: challenges related to study design and choice of proper endpoints.
Gasparini
G
G
Division of Medical Oncology, Azienda Ospedaliera Bianchi-Melacrino-Morelli, Reggio Calabria, Italy.
Gion
M
M
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors; D000483:Alleles; D015415:Biomarkers; D002986:Clinical Trials as Topic; D004268:DNA-Binding Proteins; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000235:genetics; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000235:genetics; D015316:Genetic Therapy; D006801:Humans; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000235:genetics; D009369:Neoplasms / Q000628:therapy*; D012313:RNA; D012106:Research / Q000639:trends; D019098:Telomerase / Q000096:biosynthesis* / Q000235:genetics*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D015415:Biomarkers; D004268:DNA-Binding Proteins; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; C422952:telomerase RNA; D012313:RNA; D019883:Alkyl and Aryl Transferases; C064911:p21(ras) farnesyl-protein transferase; D066246:ErbB Receptors; D019098:Telomerase